Google Shows AI Can Predict Lung Cancer from CT Scans
By HospiMedica International staff writers Posted on 01 Jun 2019 |
Google LLC (Mountain View, CA, USA) has shared new research demonstrating how artificial intelligence (AI) can predict lung cancer to boost the chances of survival for people at risk across the world.
Since 2017, Google has been exploring how AI can be used to address the challenges in screening people at a high-risk for lung cancer with lower dose CT screening that leads to unclear diagnosis, subsequent unnecessary procedures, and financial costs. Google used advances in 3D volumetric modeling along with datasets from its partners for modeling lung cancer prediction and laying the groundwork for future clinical testing.
Generally, radiologists go through hundreds of 2D images within a single CT scan with cancer being miniscule and hard to spot. Google researchers created a model that can generate the overall lung cancer malignancy prediction (viewed in 3D volume) as well as identify subtle malignant tissue in the lungs (lung nodules). The model can also factor in information from previous scans, which can be useful in predicting lung cancer risk as the growth rate of suspicious lung nodules can be an indicator of malignancy.
The researchers leveraged 45,856 de-identified chest CT screening cases and validated the results with a second dataset and also compared their results against six US board-certified radiologists. They found that when using a single CT scan for diagnosis, their model performed on par or better than the six radiologists and detected 5% more cancer cases while reducing false-positive exams by more than 11% as compared to unassisted radiologists in the study. Google’s approach achieved an AUC (a common metric used in machine learning that provides an aggregate measure for classification performance) of 94.4%.
With only 2-4% of eligible patients in the US being currently screened for lung cancer, Google’s research demonstrates the potential for AI to increase accuracy as well as consistency, which could help accelerate the adoption of lung cancer screening globally. Google now plans to conduct further studies to assess its impact and utility in clinical practice. It is collaborating with Google Cloud Healthcare and Life Sciences team to serve the model through the Cloud Healthcare API and is holding discussions with its partners across the world to continue additional clinical validation research and deployment.
Related Links:
Google
Since 2017, Google has been exploring how AI can be used to address the challenges in screening people at a high-risk for lung cancer with lower dose CT screening that leads to unclear diagnosis, subsequent unnecessary procedures, and financial costs. Google used advances in 3D volumetric modeling along with datasets from its partners for modeling lung cancer prediction and laying the groundwork for future clinical testing.
Generally, radiologists go through hundreds of 2D images within a single CT scan with cancer being miniscule and hard to spot. Google researchers created a model that can generate the overall lung cancer malignancy prediction (viewed in 3D volume) as well as identify subtle malignant tissue in the lungs (lung nodules). The model can also factor in information from previous scans, which can be useful in predicting lung cancer risk as the growth rate of suspicious lung nodules can be an indicator of malignancy.
The researchers leveraged 45,856 de-identified chest CT screening cases and validated the results with a second dataset and also compared their results against six US board-certified radiologists. They found that when using a single CT scan for diagnosis, their model performed on par or better than the six radiologists and detected 5% more cancer cases while reducing false-positive exams by more than 11% as compared to unassisted radiologists in the study. Google’s approach achieved an AUC (a common metric used in machine learning that provides an aggregate measure for classification performance) of 94.4%.
With only 2-4% of eligible patients in the US being currently screened for lung cancer, Google’s research demonstrates the potential for AI to increase accuracy as well as consistency, which could help accelerate the adoption of lung cancer screening globally. Google now plans to conduct further studies to assess its impact and utility in clinical practice. It is collaborating with Google Cloud Healthcare and Life Sciences team to serve the model through the Cloud Healthcare API and is holding discussions with its partners across the world to continue additional clinical validation research and deployment.
Related Links:
Latest AI News
Channels
Critical Care
view channel
3D Printed Functional Human Islets Could Transform Type 1 Diabetes Treatment
Type 1 diabetes (T1D) is a chronic condition in which the body’s immune system destroys insulin-producing cells in the pancreas, requiring patients to rely on regular insulin injections to manage blood sugar.... Read more
AI Model Predicts ICU mortality in Heart Failure Patients
Currently, heart failure has emerged as a significant complication during the later stages of various cardiovascular disorders. In the Intensive Care Unit (ICU), patients with heart failure often experience... Read moreSurgical Techniques
view channel
Breakthrough Polymer Significantly Improves Safety of Implantable Medical Devices
Every year, millions of patients receive implantable cardiovascular devices such as arterial and venous catheters, pacemaker leads, artificial hearts, and vascular prostheses. These devices, typically... Read more
First-Ever Technology Makes Blood Translucent During Surgery
No matter the discipline or scale, bleeding is a regular part of any surgery and can create several challenges. In operating room imaging, seeing through blood in real-time during a surgery has been a... Read more
Tibia Nailing System with Novel Side-Specific Nails to Revolutionize Fracture Surgery
Smith+Nephew (Hull, UK;) has launched its new TRIGEN MAX Tibia Nailing System for stable and unstable fractures of the tibia, including the shaft. It is the only system to now offer trauma surgeons the... Read morePatient Care
view channel
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
VR Training Tool Combats Contamination of Portable Medical Equipment
Healthcare-associated infections (HAIs) impact one in every 31 patients, cause nearly 100,000 deaths each year, and cost USD 28.4 billion in direct medical expenses. Notably, up to 75% of these infections... Read more
Portable Biosensor Platform to Reduce Hospital-Acquired Infections
Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read moreHealth IT
view channel
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read more
Smartwatches Could Detect Congestive Heart Failure
Diagnosing congestive heart failure (CHF) typically requires expensive and time-consuming imaging techniques like echocardiography, also known as cardiac ultrasound. Previously, detecting CHF by analyzing... Read moreBusiness
view channel
Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies
A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more